Congenital Cardiac Anesthesia Society
A Section of the the Society for Pediatric Anesthesia

Congenital Cardiac Anesthesia Society

  • Member Login
  • Forgot Password?
  • Join
  • Home
  • About
    • Mission Statement
    • Bylaws
    • Board of Directors
    • History
    • Past Presidents
    • Charter Members
    • CCAS Lifetime Achievement Award
    • Mailing List Rental
    • Contact Us
  • Partners
    • SPA
    • SPPM
    • PALC
    • PCICS
    • AmSECT
    • SMACT
    • CHA
    • CCAN
  • Committees
    • CCAS Committees
      • Pediatric Cardiac Anesthesiology Program Director’s Group (PCAPD) Committee
      • Communications Committee
      • CCAS-STS Database Committee
      • Education Committee
      • Global Health Committee
      • Membership Committee
      • Quality and Safety Committee
      • Research Committee
    • CCAS Special Interest Groups
      • Adult Congenital Heart Disease Special Interest Group (SIG)
      • ERAS Special Interest Group (SIG)
      • Hemostasis Special Interest Group (SIG)
      • Latin America Special Interest Group (SIG)
      • Pulmonary Hypertension Special Interest Group (SIG)
      • Trainee Special Interest Group (SIG)
  • Membership
    • Benefits of Membership
    • CCAS Member App
    • Membership Categories
    • Join CCAS
      • Online Application
      • Printable Application
    • Renew Your Dues
    • Sponsor a Member
    • Get Involved
  • Meetings
    • Upcoming Meetings
    • Past Meetings
    • Other Meetings
    • Exhibit Information
  • Education
    • CCAS Virtual Visiting Professor Program
    • CCAS Webinar Series
      • CCAS Webinar Series – Recordings
    • CCAS COVID 19 Webinar
    • ACHD-SIG Anesthesia Rounds
    • Lecture Series
    • Echo Tutorial
    • Archived Questions
    • Poll of the Month Archives
    • Review Articles
      • CCAS-CHiP Network Journal Watch Collaboration
      • SCVA Articles
    • Journals of Interest
    • Books of Interest
    • Educational Links
  • Resources
    • CCAS Position Statements
    • CCAS Committee Resources
    • CCAS Special Interest Group (SIG) Resources
    • CCAS Cognitive Aids
    • Newsletters
    • Research Resources
    • Mission Trips
    • Societies
    • Job Opportunities
  • Research
    • Research Committee
    • CCAS 2025 Meeting Scholarship for Students and Residents
    • Research Network & Collaborative Opportunities
    • Research Resources
    • Dolly D. Hansen, MD Research Award
    • Podcast Series for Aspiring CCAS Researchers
    • Highlight on a CCAS Researcher
    • Call for Surveys
    • STS-CCAS Database
    • Donate to the Dolly Hansen Fund
    • Grant Opportunities
  • Trainees
    • Introduction to Pediatric Cardiac Anesthesiology
    • Trainee Lecture Series
    • Advanced Training
    • Pediatric Cardiac Anesthesiology Fellowship Common Goals and Objectives
    • Frequently Asked Questions
    • Pediatric Cardiac Anesthesia Education Resources
    • Coaching/Mentoring Initiative
  • Patients
    • FAQs for Cardiac Anesthesia
    • FAQs for Cardiac Anesthesia – Spanish
    • SmartTots FAQs for Parents
    • Useful Resources for Parents

QOW 497

Authors: Kaitlin M. Flannery, MD, MPH - Stanford University AND Amy Babb MD - Monroe Carell Jr. Children’s Hospital, Vanderbilt


An eight-month-old boy with a history of Williams syndrome underwent repair of supravalvar aortic stenosis 24 hours ago. The blood pressure is noted to be 124/84 despite administration of additional analgesic and sedative medications. The last lactate was increased from 2.4 to 5.8, and the urine output is 0.6 cc/kg/hr. Liver transaminases have doubled over the last 24 hours. Which of the following antihypertensive medications is MOST appropriate to treat this patient?

Correct! Wrong!

EXPLANATION


Anti-hypertensive medications are frequently utilized in pediatric patients who undergo cardiac surgery. Causes of perioperative hypertension include activation of the sympathetic nervous system from excessive catecholamines, peripheral vasoconstriction, volume overload, and decreased baroreceptor sensitivity. Nitroglycerin, sodium nitroprusside, nicardipine, and clevidipine represent various vasodilator therapies used in pediatric patients after cardiac surgery. Nitroglycerin is a venodilator that is rarely effective as a monotherapy for elevated systemic vascular resistance. Sodium nitroprusside causes both arterial and venous dilatation. Due to its rapid onset of action, it is more likely to be associated with undesired hypotension during drug titration. In addition, there is a risk of cyanide toxicity with resultant hepatic dysfunction and thiocyanate toxicity with potential renal dysfunction.


Clevidipine is a dihydropyridine L-type calcium channel blocker that is used as an intravenous infusion to decrease systemic vascular resistance by direct arterial vasodilation. The mechanism of action is identical to nicardipine but with differing pharmacokinetics, which are detailed in the table below.





Clevidipine is rapidly metabolized by hydrolysis of ester linkages and occurs within the blood compartment and extravascular tissues. Therefore, drug metabolism is not affected by hepatic and/or renal function.


Clevidipine is available in a lipid emulsion that appears similar to propofol. Due to its high lipid content, administration of clevidipine and propofol infusions over prolonged periods may warrant monitoring of triglyceride levels. In addition, lipid enteral infusions for nutrition may require dose adjusting with concomitant clevidipine use to avoid hypertriglyceridemia. It should also be noted that the clevidipine preparation contains soybean oil and egg yolk phospholipid, posing a question about food allergy cross-reactivity.


The correct answer is B. Clevidipine is the correct answer because its metabolism is not affected by renal or hepatic dysfunction, which are present in this patient. Nicardipine is metabolized by the liver and thus its action may be prolonged in the setting of rising lactate and hepatic dysfunction. Sodium nitroprusside should be avoided in this patient as it is associated with a risk of cyanide and thiocyanate toxicity, which can further worsen liver and renal dysfunction, respectively.


REFERENCES


Ma M, Martin E, Algaze C, et al. Williams syndrome: supravalvar aortic, aortic arch, coronary, and pulmonary arteries: is comprehensive repair advisable and achievable? Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2023;26:2-8.


Wu M, Ryan KR, Roesenthal DN, Jahadi O, Moss J, Kwiatkowski DM. The use of clevidipine for hypertension in pediatric patients receiving mechanical circulatory support. Pediatr Crit Care Med. 2020;21(12):e1134-1139.


Aronson S, Dyke CM, Stierer KA, et al. The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008;107(4):1110-1121.


Poll of the Month

May 2025
At your institution, do you routinely send a TEG/ROTEM during the rewarming phase of cardiopulmonary bypass?
View Results
Total Answers 65
Total Votes 65

Upcoming Meeting Information


CCAS 2026 Annual Meeting

March 12, 2026
Sheraton Denver Downtown
Denver, CO

 

 

 

 

Join CCAS
Renew
Donate
Get Involved
Upcoming
Job Postings
  • Member Login
  • Forgot Password?
2209 Dickens Road, Richmond, VA 23230 • 804-282-9780 • [email protected]
Copyright © 2025 The Congenital Cardiac Anesthesia Society | View Privacy Policy